GlucoGuard Receives $43 Million Enterprise Valuation Research Report
Del Mar, California--(Newsfile Corp. - June 10, 2025) - Harbinger Research, LLC an independent equity research firm with a focus on the small cap and microcap stocks, announced today that it has published a new research report on American Diversified Holdings Corporation/GlucoGuard (OTC Pink: ADHC).
The report includes a valuation analysis, multi-year financial forecast model, and a value estimate of the Company and its shares. The report puts a fully diluted price target of .0012 equivalent to a $43 million enterprise valuation, assuming full dilution for required developmental capital at the current stock price. As the stock price increases, the dilution would decline accordingly raising the price target. Currently, ADHC is working with Investment Partners on Capital Formation that will benefit the enterprise valuation model utilizing non-dilutive or controlled dilutive financial models.
As the development process continues further Intellectual Property filings with the USPTO is anticipated further enhancing GlucoGuards' valuation proposition.
A main catalyst for GlucoGuards valuation will be fully described in future releases with a full analysis of the artificial intelligence and predictive learning aspect of the Bio Tracking and recording of blood Glucose levels.
To access the research report, please visit the Harbinger Research website at:
2023-06-02 American Diversified Holdings Corp. Coverage Initiation Report (d1io3yog0oux5.cloudfront.net)
"Management views the $43 M enterprise value to be conservative due to ability of the GlucoGuard technology to meet the unmet need of hypoglycemia and the severe problems of "Death in Bed"," commented ADHC. "Additionally, this report does not incorporate GlucoGuards' AI and Predictive learning software components and related IP due to its developing nature," concluded ADHC.
Key Aspects of the Report
537mm Diabetic Patients Worldwide.
37 mm Diabetic Patients In the US.
3.7 Type 1 Diabetics in the US.
190k to 380K Potential Patients in the US.
a potential market of $360 MM to $720MM in revenues.
IN ADDITIONAL NEWS
ADHC is in negotiations for a strategic partnership to license the GlucoGuard Technology to the Eurpean Union for upfront cash payments, milestone cash payments and cash payment royalties from revenues.
Arete Biosciences development contract has been initially funded and is expected to expand into patient studies.
ADHC 6-15-25 Quartely disclosure filing is expected to be filed this week ahead of the deadline.
Dexcom APP integration and AI software system is under review and should be proceeding to the next phase in the near term.
Patent Counsel is updating GlucoGuards' IP with the USPTO.
Shareholders should anticipate and continual stream of announcements on these developments and more in the near future.
About Harbinger Research, LLC
Harbinger Research, LLC is one of a new breed of issuer-sponsored research boutiques, providing unbiased equity research coverage to smaller issuers that cannot attract research coverage from traditional brokerage firm's research departments. Our mission is to help both investors and public issuers by improving the availability of issuer information and by providing sound, unbiased analysis of our issuer clients' businesses, industries, and current market valuation.
The policies of Harbinger Research, LLC require that all personnel strictly adhere to the CFA Institute's Code of Ethics and Standards of Professional Conduct, and its Best Practice Guidelines Governing Analyst / Corporate Issuer Relations. Please see www.cfainstitute.org for more information.
To view our disclosures and disclaimers, or for more information, visit www.harbingerresearch.com.
Harbinger Research, LLC Brian Connell, CFA Senior Research Analyst brian@harbingerresearch.com.
ABOUT GLUCOGUARD
GlucoGuard, a Division of American Diversified Holdings Corporation is a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com. Contact: Phone: 817-525-0057Email: info@GlucoGuardSleep.com
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7822/255016_6d0a10f01418bade_001full.jpg
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/7822/254131_81935201249818a5_002full.jpg
ABOUT AMERICAN DIVERSIFIED HOLDINGS CORPORATION
John Cacchioli, CEO American Diversified Holdings Corporation Telephone: (212) 537-5900
INVESTOR HOTLINE 858-325-7098 Email: JC@American-Diversified.com ; ADHCInvestor@Yahoo.com
SOCIAL MEDIA
TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
SOURCE: American Diversified Holdings Corporation
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/255016
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) ('AIM' or the 'Company') today announced a reverse stock split ('Reverse Stock Split') of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American's Listing Qualifications. At a Special Meeting of Stockholders held on April 30, 2025, the Company's stockholders approved a series of alternate amendments to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company's Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@
Yahoo
10 hours ago
- Yahoo
01 Communique Engages Oak Hill
Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - 01 Communique Laboratory Inc. (TSXV: ONE) (OTC Pink: OONEF) (the "Company"), one of the first-to-market, enterprise level cybersecurity providers for the quantum computing era, is pleased to announce that it has retained the services of Oak Hill Financial Inc. ("Oak Hill") to provide, among other things, investor relations, business and capital markets advisory services to the Company (the "Services"). Oak Hill is a Toronto-based investor relations and capital markets advisory firm that has been engaged to, among other things, heighten market and brand awareness for the Company as well as to broaden the awareness of the Company within the investment community via email and phone campaigns. The agreement with Oak Hill is effective as of June 10, 2025 and has an initial period of two months. The agreement is subject to TSX Venture Exchange approval. Oak Hill has agreed to comply with all applicable securities laws and policies of the TSX Venture Exchange in providing its Services. In connection with the Services, Oak Hill will be paid a monthly fee of $12,000, plus applicable taxes. Neither Oak Hill nor its principals have any interest, directly or indirectly, in the Corporation or its securities, or any right or intent to acquire such an interest. About 01 Communique Established in 1992, 01 Communique (TSXV: ONE) (OTC Pink: OONEF) has always been at the forefront of technology. The Company's cyber security business unit focuses on post-quantum cybersecurity with the development of its IronCAP™ product line. IronCAP™'s technologies are patent-protected in the U.S.A. by its patents #11,271,715 and #11,669,833. The Company's remote access business unit provides its customers with a suite of secure remote access services and products under its I'm InTouch and I'm OnCall product offerings. The remote access offerings are protected in the U.S.A. by its patents #6,928,479 / #6,938,076 / #8,234,701; in Canada by its patents #2,309,398 / #2,524,039 and in Japan by its patent #4,875,094. For more information, visit the Company's web site at and Neither TSX Venture Exchange ("TSX-V") nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. INVESTOR CONTACT:Brian StringerChief Financial Officer01 Communique(905) 795-2888 To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
16 hours ago
- Yahoo
VAYK to Acquire Up to $9 million in Time-share Vacation Properties Through Non-Cash Deals
ATLANTA, June 11, 2025 /PRNewswire/ -- Vaycaychella, Inc. (OTC Pink: VAYK) ("VAYK") management announced today the launch of a campaign to acquire time-share properties through non-cash deals. The company has reached an MOU to acquire $90,000 worth of timeshare in a non-cash deal, with the potential to increase the deal size to $9.0 million. Timeshares Resold at Deep Discounts Timeshares are often underperforming assets for most current owners. Many individuals purchase timeshares during vacation trips, mistakenly believing they will frequently return. However, their initial excitement often fades, leading to underutilization of their timeshare rights. Additionally, they lack the time or expertise to resell their annual rights, while still paying maintenance fees that may increase annually. "For these reasons, timeshare rights are resold for cash at deep discounts," said Jason Armstrong, Director of the Board at VAYK. "According to a major resale broker, in 2024, a top Disney Vacation Club (DVC) resort like Disney's Grand Floridian Resort and Spa costs $230 per point when purchased directly from Disney. However, it was resold by this broker at an average price of $151 per point. In other words, it is more than one-third cheaper to resell timeshare." Mutually Beneficial Non-Cash Deals at Fair Value Instead, current owners may sell their timeshares to VAYK at fair value in non-cash deals, paid in restricted stocks or preferred convertible stocks. "This will be mutually beneficial," explained Armstrong. "The current owner will not suffer a financial loss and will have an upside if our share price increases. Meanwhile, those timeshares, while underperforming for current owners, can be well-managed to maximize cash revenue, in the hands of professional managers." Economic scalability is another factor. "An individual with only one timeshare will never reach adequate efficiency to manage it. In contrast, a company like ours, with 20 or 50 timeshares, can manage them collectively and achieve much higher efficiency," said Armstrong. May Exceeding 100% Revenue Growth Goal in 2025 VAYK is a vacation property renovation and operation company, focusing on short-term rentals. It reported $668K in operating revenue for 2024, with approximately $150K profit. The company has projected 100% operating revenue growth for 2025, after reporting $427,000 in revenue for the first quarter of 2025, and is set to reach about $1.5 million in annual revenue. This projection is based on its current line of business. If any new business plans are realized and generate significant revenue in 2025, the company will likely exceed its 100% revenue growth projection. "This is a huge turnaround," emphasized Armstrong. "Three years ago, this company was a sinking ship, in deep debt of over $3 million and at risk of completely losing its overseas investment. Since the new management team took over, we have eliminated $2.55 million in debt, of which about $2.37 million was complete forgiveness or cancellation; we have sold our legacy investment overseas for a $320K profit; we have secured a joint-venture agreement to renovate and operate the famous Rufus Rose House, a downtown Atlanta historic landmark; and we have closed an acquisition of a property renovation company, expecting $1.4 million in operating revenue mostly generated from this line of business." "Most importantly, we have achieved all of this without using any toxic debt financing. We have not issued any free trade shares for more than three years, and our interest costs have dramatically dropped to only about $81K in 2024, compared to $236K in interest payments in 2023," Armstrong highlighted. Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. VAYK Contact:Contact@ 470-804-7144 View original content: SOURCE Vaycaychella, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
